【摘要】

摘要：目的 探讨精神分裂症阴性症状患者采用齐拉西酮与奥氮平治疗临床疗效。
方法 按照治疗
方法不同将医院收治的90例精神分裂症阴性症状患者分为对照组与观察组，各45例。对照组采用奥氮平治疗，首次剂量为5mg/次，2次/d，之后依据患者临床状态每2 d增加5mg，2周内增加至15~20mg/d。观察组采用齐拉西酮治疗，首次剂量为20mg/次，2次/d，与食物同时服用，1周内增加至120~160 mg/d。分别于治疗4周、8周、12周评价两组临床疗效和阴性症状量表评分，记录两组治疗期间所发生的不良反应。
结果 观察组治疗4周、8周、12周时临床有效率与对照组相比较，差异无统计学意义，P>0.05；两组治疗4周、8周、12周时阴性症状量表评分明显低于治疗前，P<0.05；然两组间相比较，P>0.05。两组阳性症状于治疗12周时评分明显低于治疗前、治疗4周、8周，P<0.05；组间相比较，P>0.05。对照组于治疗第8周时开始变化且低于治疗前，P<0.05。治疗组精神病理评分于治疗12周开始变化，对照组于治疗第8周时开始变化，且低于治疗前，P<0.05；但组间比较，P>0.05；观察组治疗期间不良反应率26.67%(12/45)，明显低于对照组46.67%(21/45)，χ2=3.875，P=0.048。
结论 临床采用奥氮平与齐拉西酮治疗精神分裂症阴性症状患者，均可显著改善其临床症状，但两者疗效相当，采用齐拉西酮治疗产生的不良反应较少，因此可作为临床治疗精神分裂症阴性症状患者的首选药物。

【Abstract】

Abstract：objective To investigate the clinical efficacy of ziprasidone and olanzapine in patients with negative symptoms of schizophrenia.
Methods According to different treatment methods, 90 patients with negative symptoms of schizophrenia admitted to hospital were divided into control group and observation group, 45 cases each. The control group was treated with olanzapine, and the first dose was 5 mg/dose, twice/d, then increased by 5 mg every 2 d and increased to 15 to 20 mg/d within 1 weeks. The observation group was treated with ziprasidone, and the first dose was 20 mg/times, 2 times/d, taken with food at the same time, and increased to 120-160 mg/d within 1 week. The clinical efficacy and negative symptom scores of the two groups were evaluated at 4 weeks, 8 weeks, and 12 weeks respectively, and the adverse reactions occurred during the two groups of treatment were recorded.
Results There was no significant difference in the clinical efficacy rate between the observation group and the control group at 4 weeks, 8 weeks, and 12 weeks (P>0.05). The negative symptom scores were significantly lower at the 4th, 8th, and 12th week in the treatment group. Before treatment, P<0.05; compared between the two groups, P>0.05. The positive symptoms of the two groups were significantly lower than those before treatment, 4 weeks, and 8 weeks of treatment at the 12th week of treatment (P<0.05), and P>0.05 between groups. The control group began to change at the 8th week of treatment and was lower than before treatment, P<0.05. The treatment group psychopathological score began to change at 12 weeks of treatment, the control group began to change at the 8th week of treatment, and was lower than before treatment, P <0.05; but between the groups, P> 0.05;The adverse reaction rate in the observation group during treatment was 26.67% (12/45), which was significantly lower than the control group (46.67% (21/45), χ2=3.875, P=0.048.
Conclusion   Clinical application of olanzapine and ziprasidone in patients with negative symptoms of schizophrenia can significantly improve the clinical symptoms, but the two are of similar efficacy, and the adverse reactions generated by ziprasidone treatment are less, so it can be used as a clinical treatment spirit. The preferred drug for patients with negative symptoms of schizophrenia.